168 related articles for article (PubMed ID: 21981936)
21. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
Herman GA; Mistry GC; Yi B; Bergman AJ; Wang AQ; Zeng W; Chen L; Snyder K; Ruckle JL; Larson PJ; Davies MJ; Langdon RB; Gottesdiener KM; Wagner JA
Br J Clin Pharmacol; 2011 Mar; 71(3):429-36. PubMed ID: 21284702
[TBL] [Abstract][Full Text] [Related]
22. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
Skalli S; Wion-Barbot N; Baudrant M; Lablanche S; Benhamou PY; Halimi S
Diabet Med; 2010 Apr; 27(4):486-7. PubMed ID: 20536525
[No Abstract] [Full Text] [Related]
23. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
Pendergrass M; Fenton C; Haffner SM; Chen W
Diabetes Obes Metab; 2012 Jul; 14(7):596-600. PubMed ID: 22268550
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Modification of Diet in Renal Disease Study and Cockcroft-Gault equations for sitagliptin dosing.
McFarland MS; Markley BM; Zhang P; Hudson JQ
J Nephrol; 2012; 25(4):515-22. PubMed ID: 21928236
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):745-58. PubMed ID: 22587686
[TBL] [Abstract][Full Text] [Related]
27. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
Perusicová J
Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
[TBL] [Abstract][Full Text] [Related]
28. Sitagliptin/metformin (Janumet) for type 2 diabetes.
Med Lett Drugs Ther; 2007 Jun; 49(1262):45-7. PubMed ID: 17541377
[No Abstract] [Full Text] [Related]
29. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Herman GA; Stein PP; Thornberry NA; Wagner JA
Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
[TBL] [Abstract][Full Text] [Related]
30. Sitagliptin.
Drucker D; Easley C; Kirkpatrick P
Nat Rev Drug Discov; 2007 Feb; 6(2):109-10. PubMed ID: 17342863
[No Abstract] [Full Text] [Related]
31. Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes.
Yuan G; Jia J; Zhang C; Yu S; Dong S; Ye J; Zhu T; Tang B; Qian W; Wang D; Yang L; Zhou L; Mao C
Endocr J; 2014; 61(5):513-21. PubMed ID: 24621778
[TBL] [Abstract][Full Text] [Related]
32. Severe leucopenia associated with Sitagliptin use.
Pitocco D; Zaccardi F; Martini F; Scavone G; Musella T; Caputo S; Ghirlanda G
Diabetes Res Clin Pract; 2011 Feb; 91(2):e30-2. PubMed ID: 21035885
[TBL] [Abstract][Full Text] [Related]
33. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
Tremblay AJ; Lamarche B; Deacon CF; Weisnagel SJ; Couture P
Diabetes Obes Metab; 2011 Apr; 13(4):366-73. PubMed ID: 21226820
[TBL] [Abstract][Full Text] [Related]
34. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
Musch A; Heinzl S
Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
[No Abstract] [Full Text] [Related]
35. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.
Saito T; Ohnuma K; Suzuki H; Dang NH; Hatano R; Ninomiya H; Morimoto C
Diabetes Res Clin Pract; 2013 Oct; 102(1):e8-e12. PubMed ID: 23937822
[TBL] [Abstract][Full Text] [Related]
36. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
Xu L; Spinas GA; Niessen M
Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
[No Abstract] [Full Text] [Related]
37. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
38. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
Mori Y; Taniguchi Y; Matsuura K; Sezaki K; Yokoyama J; Utsunomiya K
Diabetes Technol Ther; 2011 Jul; 13(7):699-703. PubMed ID: 21504334
[TBL] [Abstract][Full Text] [Related]
39. DPP-IV inhibitor-associated arthralgias.
Chaicha-Brom T; Yasmeen T
Endocr Pract; 2013; 19(2):377. PubMed ID: 23598537
[No Abstract] [Full Text] [Related]
40. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
Guillermin AL; Lloyd A; Best JH; DeYoung MB; Samyshkin Y; Gaebler JA
J Med Econ; 2012; 15(4):654-63. PubMed ID: 22369345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
